IDXX Stock: IDEXX Laboratories, Inc. Stock Price, Analysis & Insights
Get live idxx stock price $670.21, comprehensive IDEXX Laboratories, Inc. stock analysis, charts, news, and expert forecast. Real-time idxx stock data and investment insights.
Loading chart...
Company Overview
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Company Information
- CEO
- Jonathan J. Mazelsky
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 11000
Contact Information
- Website
- https://www.idexx.com
- Address
- One IDEXX Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 53.3)
✓ Higher growth potential with elevated volatility (Beta: 1.69)
Business Model & Strategy
IDEXX Laboratories, Inc. operates in the Medical - Diagnostics & Research industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a mid-cap company, IDEXX Laboratories, Inc. benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Jonathan J. Mazelsky, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Diagnostics & Research model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
IDEXX Laboratories, Inc. competes in the Medical - Diagnostics & Research within the broader Healthcare. With 53.5 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, IDEXX Laboratories, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating IDEXX Laboratories, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for IDEXX Laboratories, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for IDEXX Laboratories, Inc.
- ⚠Investors should consider how IDEXX Laboratories, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 53.3) requires strong growth to justify
Market Cap
53.52B
P/E Ratio
53.28
Beta
1.69
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 53.52B market capitalization
- Trading Volume: 574.38K shares traded today
- Price Range: 52-week range of $356.14 - $735.00
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. (IDXX) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 53.52B, the company represents a significant player in its market. The stock is currently trading at $670.21 with a positivedaily change of 0.18%.
The company's 11000 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 53.28, beta of 1.69, and 52-week price range from $356.14 to $735.00when evaluating investment opportunities.
Why Invest in IDEXX Laboratories, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Jonathan J. Mazelsky
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.